These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 26576544)

  • 1. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.
    Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
    Osteoporos Int; 2016 Jan; 27(1):387-96. PubMed ID: 26576544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study.
    Bondo L; Eiken P; Abrahamsen B
    Osteoporos Int; 2013 Jan; 24(1):245-52. PubMed ID: 22638712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate use after clinical fracture and risk of new fracture.
    Bergman J; Nordström A; Nordström P
    Osteoporos Int; 2018 Apr; 29(4):937-945. PubMed ID: 29397408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.
    Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
    Osteoporos Int; 2017 May; 28(5):1587-1595. PubMed ID: 28083667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates and mortality: confounding in observational studies?
    Bergman J; Nordström A; Hommel A; Kivipelto M; Nordström P
    Osteoporos Int; 2019 Oct; 30(10):1973-1982. PubMed ID: 31367949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Following hip fracture, hospital organizational factors associated with prescription of anti-osteoporosis medication on discharge, to address imminent refracture risk: a record-linkage study.
    Patel R; Judge A; Johansen A; Javaid MK; Griffin XL; Chesser T; Griffin J; Marques EMR; ; Ben-Shlomo Y; Gregson CL
    J Bone Miner Res; 2024 Aug; 39(8):1071-1082. PubMed ID: 38988134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoporosis medication and reduced mortality risk in elderly women and men.
    Center JR; Bliuc D; Nguyen ND; Nguyen TV; Eisman JA
    J Clin Endocrinol Metab; 2011 Apr; 96(4):1006-14. PubMed ID: 21289270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
    Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
    Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Osteoporosis Medications Associated with Decreased Mortality after Hip Fracture.
    Wang PW; Li YZ; Zhuang HF; Yu HM; Cai SQ; Xu H; Chen ZH; Lin JK; Yao XD
    Orthop Surg; 2019 Oct; 11(5):777-783. PubMed ID: 31429532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate use and subsequent hip fracture in South Korea.
    Lee YK; Ha YC; Choi HJ; Jang S; Park C; Lim YT; Shin CS
    Osteoporos Int; 2013 Nov; 24(11):2887-92. PubMed ID: 23681088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality after hip fracture in Austria 2008-2011.
    Brozek W; Reichardt B; Kimberger O; Zwerina J; Dimai HP; Kritsch D; Klaushofer K; Zwettler E
    Calcif Tissue Int; 2014 Sep; 95(3):257-66. PubMed ID: 24989776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
    Bliuc D; Tran T; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse RG; Kaiser S; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR;
    Osteoporos Int; 2019 Apr; 30(4):817-828. PubMed ID: 30607457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refracture following fracture liaison service assessment illustrates the requirement for integrated falls and fracture services.
    Langridge CR; McQuillian C; Watson WS; Walker B; Mitchell L; Gallacher SJ
    Calcif Tissue Int; 2007 Aug; 81(2):85-91. PubMed ID: 17629737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening and treatment of osteoporosis after hip fracture: comparison of sex and race.
    Antonelli M; Einstadter D; Magrey M
    J Clin Densitom; 2014; 17(4):479-83. PubMed ID: 24657109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of bipolar hemiarthroplasty replacement and fosamax in the retrospective cohort study of refracture and mortality of hip fractured patients.
    Chen JS; Chen PM; Lin CY; Chen RF; Lee PY
    Pak J Pharm Sci; 2016 May; 29(3 Suppl):1071-5. PubMed ID: 27383485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of outcomes and management of patients post fragility fractures in China.
    Wang O; Hu Y; Gong S; Xue Q; Deng Z; Wang L; Liu H; Tang H; Guo X; Chen J; Jia X; Xu Y; Lan L; Lei C; Dong H; Yuan G; Fu Q; Wei Y; Xia W; Xu L
    Osteoporos Int; 2015 Nov; 26(11):2631-40. PubMed ID: 25966892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary osteoporosis prevention: three-year outcomes from a Fracture Liaison Service in elderly hip fracture patients.
    González-Quevedo D; Rubia-Ortega C; Sánchez-Delgado A; Moriel-Garceso D; Sánchez-Siles JM; Bravo-Bardají M; García-de-Quevedo D; Tamimi I
    Aging Clin Exp Res; 2024 May; 36(1):103. PubMed ID: 38704788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in and relation between hip fracture incidence and osteoporosis medication utilization and prices in Estonia in 2004-2015.
    Laius O; Pisarev H; Maasalu K; Kõks S; Märtson A
    Arch Osteoporos; 2017 Dec; 12(1):48. PubMed ID: 28497319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractures and mortality in relation to different osteoporosis treatments.
    Yun H; Delzell E; Saag KG; Kilgore ML; Morrisey MA; Muntner P; Matthews R; Guo L; Wright N; Smith W; Colón-Emeric C; O'Connor CM; Lyles KW; Curtis JR
    Clin Exp Rheumatol; 2015; 33(3):302-9. PubMed ID: 25068266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.